197 related articles for article (PubMed ID: 23588203)
61. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
[TBL] [Abstract][Full Text] [Related]
62. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
Zhu K; Du D; Yang R; Tao H; Zhang H
Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
[TBL] [Abstract][Full Text] [Related]
63. Jarid2 enhances the progression of bladder cancer through regulating PTEN/AKT signaling.
Wang X; Lyu J; Ji A; Zhang Q; Liao G
Life Sci; 2019 Aug; 230():162-168. PubMed ID: 31125562
[TBL] [Abstract][Full Text] [Related]
64. H3K27me3 may be associated with Oct4 and Sox2 in mouse preimplantation embryos.
Wu FR; Zhang Y; Ding B; Lei XH; Huang JC; Wang CH; Liu Y; Wang R; Li WY
Genet Mol Res; 2014 Dec; 13(4):10121-9. PubMed ID: 25501223
[TBL] [Abstract][Full Text] [Related]
65. The role of polycomb repressive complexes in biliary tract cancer.
Mayr C; Neureiter D; Wagner A; Pichler M; Kiesslich T
Expert Opin Ther Targets; 2015 Mar; 19(3):363-75. PubMed ID: 25424424
[TBL] [Abstract][Full Text] [Related]
66. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.
Rizk M; Rizq O; Oshima M; Nakajima-Takagi Y; Koide S; Saraya A; Isshiki Y; Chiba T; Yamazaki S; Ma A; Jin J; Iwama A; Mimura N
Cancer Sci; 2019 Dec; 110(12):3695-3707. PubMed ID: 31571328
[TBL] [Abstract][Full Text] [Related]
67. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
[TBL] [Abstract][Full Text] [Related]
68. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
69. Targeting of cancer stem cells by inhibitors of DNA and histone methylation.
Momparler RL; Côté S
Expert Opin Investig Drugs; 2015; 24(8):1031-43. PubMed ID: 26004134
[TBL] [Abstract][Full Text] [Related]
70. Predicting involvement of polycomb repressive complex 2 in direct conversion of mouse fibroblasts into induced neural stem cells.
Yaqubi M; Mohammadnia A; Fallahi H
Stem Cell Res Ther; 2015 Mar; 6(1):42. PubMed ID: 25890371
[TBL] [Abstract][Full Text] [Related]
71. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Martin MC; Zeng G; Yu J; Schiltz GE
J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
[TBL] [Abstract][Full Text] [Related]
72. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
73. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
Knutson SK; Kawano S; Minoshima Y; Warholic NM; Huang KC; Xiao Y; Kadowaki T; Uesugi M; Kuznetsov G; Kumar N; Wigle TJ; Klaus CR; Allain CJ; Raimondi A; Waters NJ; Smith JJ; Porter-Scott M; Chesworth R; Moyer MP; Copeland RA; Richon VM; Uenaka T; Pollock RM; Kuntz KW; Yokoi A; Keilhack H
Mol Cancer Ther; 2014 Apr; 13(4):842-54. PubMed ID: 24563539
[TBL] [Abstract][Full Text] [Related]
74. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.
Moore HM; Gonzalez ME; Toy KA; Cimino-Mathews A; Argani P; Kleer CG
Breast Cancer Res Treat; 2013 Apr; 138(3):741-52. PubMed ID: 23539298
[TBL] [Abstract][Full Text] [Related]
75. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
76. New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs.
Danishuddin ; Subbarao N; Khan M; Alouffi S; Khan S
Curr Drug Targets; 2021; 22(11):1198-1206. PubMed ID: 33588726
[TBL] [Abstract][Full Text] [Related]
77. PRC2.1 and PRC2.2 Synergize to Coordinate H3K27 Trimethylation.
Healy E; Mucha M; Glancy E; Fitzpatrick DJ; Conway E; Neikes HK; Monger C; Van Mierlo G; Baltissen MP; Koseki Y; Vermeulen M; Koseki H; Bracken AP
Mol Cell; 2019 Nov; 76(3):437-452.e6. PubMed ID: 31521505
[TBL] [Abstract][Full Text] [Related]
78. The polycomb repressive complex 2 is a potential target of SUMO modifications.
Riising EM; Boggio R; Chiocca S; Helin K; Pasini D
PLoS One; 2008 Jul; 3(7):e2704. PubMed ID: 18628979
[TBL] [Abstract][Full Text] [Related]
79. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
Barsotti AM; Ryskin M; Rollins RA
Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
[No Abstract] [Full Text] [Related]
80. The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells.
Streubel G; Watson A; Jammula SG; Scelfo A; Fitzpatrick DJ; Oliviero G; McCole R; Conway E; Glancy E; Negri GL; Dillon E; Wynne K; Pasini D; Krogan NJ; Bracken AP; Cagney G
Mol Cell; 2018 Apr; 70(2):371-379.e5. PubMed ID: 29606589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]